Active Pharmaceutical Ingredients
Lansoprazole Delayed Release (DR) Pellets are gastro-resistant, enteric-coated pellets formulated to inhibit gastric acid secretion effectively. These pellets are designed to protect Lansoprazole—a proton pump inhibitor (PPI)—from degradation in the acidic environment of the stomach, ensuring targeted release in the intestine. Pelletization allows for enhanced drug stability, uniform dosing, and flexibility in formulation for oral capsules or sachets. Custom strengths and coating profiles are available to meet various market and regulatory needs.
| Component | Function |
|---|---|
| Lansoprazole | Active Pharmaceutical Ingredient (API) |
| Sugar Spheres / MCC Pellets | Inert core / Neutral starter spheres |
| HPMC / PVP | Binder / Layering polymer |
| Methacrylic Acid Copolymers (e.g., Eudragit L30D-55) | Enteric coating polymer for delayed release |
| Triethyl Citrate / PEG 6000 | Plasticizer to enhance coating flexibility |
| Talc / Colloidal Silicon Dioxide | Anti-adherent / Glidant |
| Purified Water | Solvent (evaporated during processing) |
Salius Pharma offers Lansoprazole Delayed Release (DR) Pellets manufactured in USFDA-approved, WHO-GMP, and ISO-certified facilities in India, ensuring global quality standards and regulatory compliance. Our pellets are developed using optimized enteric coating technologies to ensure acid resistance and targeted intestinal release. Available in customized strengths and pellet sizes, they are ideal for capsule or sachet formulations. With proven export capabilities across Africa, Southeast Asia, CIS, and LATAM, Salius provides end-to-end support—from formulation development and documentation (CTD, CoA, MSDS) to reliable global logistics.
We ensure prompt and reliable shipping worldwide. Delivery times may vary depending on destination, order volume, and regulatory requirements.
Looking to source Lansoprazole DR Pellets or other high-quality pharmaceutical pellet formulations?
Whether you need Active Pharmaceutical Ingredients (APIs), excipients, or regulatory support, our team is ready to provide reliable, compliant, and cost-effective solutions tailored to your market needs.
The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.
Any patented products are excluded from our offerings in regions where such patents are currently in force.
Lansoprazole DR Pellets are enteric-coated using polymers such as Eudragit L30D-55 to protect the API from gastric acid, ensuring targeted release in the small intestine for effective acid suppression.
Yes, drug loading (typically 8.5%–12.5%), pellet size, and coating thickness can be customized to meet formulation and bioequivalence requirements.
Salius Pharma supplies Lansoprazole DR Pellets to Africa, Southeast Asia, CIS countries, and LATAM, with full regulatory and logistics support.
We provide GMP-compliant manufacturing, Certificate of Analysis (CoA), MSDS, stability data, and complete regulatory documentation for international markets.